Seegene Unveils STAgora™: The Future of Infectious Disease Analysis
Seegene Inc., a global frontrunner in molecular diagnostic solutions, recently announced the launch of
STAgora™, a groundbreaking platform aimed at transforming how infectious diseases are monitored and managed. This state-of-the-art system is engineered for real-time intelligence, combining diagnostic data with advanced statistical models to redefine the world's approach to disease outbreak detection and response.
In a world increasingly challenged by infectious diseases, STAgora™ promises to deliver unprecedented visibility into outbreak data across various geographical areas. The platform leverages
real-time diagnostic results to visualize trends at local, national, and continental levels, ultimately equipping healthcare professionals with immediate access to diagnostic reports and structured statistical analyses. With customizable dashboards and real-time alert functions, STAgora™ enables quick decision-making to combat disease spread effectively.
One of the standout features of STAgora™ is its capacity to track individual cases alongside broader outbreaks. This dual monitoring capability enhances situational awareness, thus allowing public health responses to be both timely and data-driven. This tool aims to provide national and global health authorities with real-time epidemiological information, which in turn supports effective decision-making and the development of strategies to mitigate large-scale disease outbreaks.
Equipped with over
40 built-in statistical tools, STAgora™ facilitates early detection of abnormal pathogen patterns while supporting predictive modeling for seasonal trends and emerging outbreaks. Users are empowered to monitor individual infections, analyze coinfections based on symptoms, and compute real-time infection rate trends, transforming static data into forward-looking intelligence that guides proactive interventions.
Unlike traditional outbreak surveillance systems that rely on retrospective data, STAgora™ performs
real-time analyses of PCR-derived diagnostics. This hallmark feature ensures immediate visibility into pathogen spread and, using AI-driven algorithms, can forecast potential future outbreaks. As Young-Seag Baeg, Seegene’s Strategic Planning Director explains, “The key differentiator of STAgora™ is its unique architecture, which aggregates real-time diagnostic data from around the world into a unified analytical platform.”
When paired with Seegene's proprietary quantitative syndromic PCR technology, STAgora™ not only enhances visibility for single pathogen infections but also for simultaneous infections by multiple pathogens. This comprehensive diagnostic insight allows medical personnel to make faster, more informed decisions at the point of care. Daniel Shin, Seegene's Executive Vice President, emphasizes the importance of timely and accurate data interpretation: “During the COVID-19 pandemic, we saw how critical swift, precise diagnostic data interpretation was for shaping public health policies and clinical outcomes.”
As we now face complex challenges such as antimicrobial resistance, viral mutations, and coinfections, the ability to distill actionable insights from diagnostic data is becoming a cornerstone of clinical innovation and a vital pillar of global health security.
STAgora™ is set to be officially introduced at the 2025 meeting of the
Association for Diagnostics Laboratory Medicine (ADLM), scheduled for July 27-31 in Chicago, USA. At this prominent event, Seegene will showcase the platform's key capabilities, including its integration with
CURECA™, Seegene’s fully automated, remote-controlled PCR system. The ADLM 2025 event will also serve as a platform for Seegene to explore collaborations and partnerships with healthcare leaders and clients globally.
With the introduction of STAgora™, Seegene is paving the way for a faster, smarter global health defense system. By integrating real-time molecular diagnostics, AI-driven analytics, and global data integration, STAgora™ marks a strategic advancement toward developing a smart public health infrastructure capable of proactively responding to emerging threats. Seegene envisions this platform as a cornerstone of the global infectious disease response framework, enhancing insights and preparedness in diagnostics.
About Seegene
Founded over two decades ago, Seegene has extensive experience in research, development, and manufacturing within the realm of real-time syndromic PCR technologies. This expertise was especially highlighted during the COVID-19 pandemic, where Seegene supplied over 340 million COVID-19 tests to more than 100 countries. Seegene’s real-time syndromic PCR technology is celebrated for its capability to simultaneously analyze up to 14 pathogens that cause similar symptoms in a single tube, providing quantitative information.
About CURECA™
CURECA™ (Continuous, Unlimited, Random Access, Expandable, and Customizable Automation) is Seegene’s state-of-the-art fully automated PCR system that eliminates manual processes, enabling continuous real-time testing. This unified platform is designed for 24/7 operation without human intervention. A key component, CPS, is touted as the world's first automated pretreatment system capable of handling various sample types, including blood, feces, sputum, and urine. CURECA™ supports both centralized and decentralized laboratories, offering scalable automation and flexible adoption, making it invaluable in settings with limited space or personnel.
For more information, visit
Seegene.com and follow us on
LinkedIn.